A significant breakthrough in contemporary management of HF was the finding that treatment with SGLT2 inhibitors was associated with a lower risk of HF hospitalization in patients with T2D and CV disease or at high risk thereof. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.